hronic cough has a substantial adverse impact on quality of life. 1,2 Although many patients with chronic cough benefi t from a systematic approach to the evaluate of the aerodigestive tract, 3 it may take time for treatments to control the cough. In addition, a subgroup of patients continues to cough despite appropriate treatment directed at possible causes. 4 These patients with diffi cult-to-control cough would benefi t from safe, effective, nonhabituating, and nonnarcotic cough treat ment. 5, 6 There are many reports in the medical literature of nebulized lidocaine providing temporary relief from cough. The literature consists mainly of small case series describing shortterm nebulized lidocaine use to control cough in the ED or in the operating room (fentanyl-induced cough). 7-14 The non-US Food and Drug Administration label use of nebulized lidocaine for cough was reviewed. 15 The pharmacokinetics of repeated treatments of nebulized lidocaine for chronic cough has not been 
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Original Research C hronic cough has a substantial adverse impact on quality of life. 1, 2 Although many patients with chronic cough benefi t from a systematic approach to the evaluate of the aerodigestive tract, 3 it may take time for treatments to control the cough. In addition, a subgroup of patients continues to cough despite appropriate treatment directed at possible causes. 4 These patients with diffi cult-to-control cough would benefi t from safe, effective, nonhabituating, and nonnarcotic cough treat ment. 5, 6 There are many reports in the medical literature of nebulized lidocaine providing temporary relief from cough. The literature consists mainly of small case series describing shortterm nebulized lidocaine use to control cough in the ED or in the operating room (fentanyl-induced cough). [7] [8] [9] [10] [11] [12] [13] [14] The non-US Food and Drug Administration label use of nebulized lidocaine for cough was reviewed. 15 The pharmacokinetics of repeated treatments of nebulized lidocaine for chronic cough has not been phone. The questionnaire was administered over the phone if the patient provided verbal consent to participate in the survey. Data obtained by phone were excluded from analysis if the patient did not have written research authorization consent on fi le or did not return the research authorization form sent after the phone interview. Any adverse event reported was further evaluated with a follow-up phone interview conducted by a pulmonary nurse. A structured interview form was used to obtain more details of the reported adverse events.
Analysis
Descriptive statistics were used to elucidate the demographic data of the survey responders. Only data from patients who actually used the treatment was included in the analysis. Effi cacy was tested through symptom rating (scale, 0-10) that compared before and after treatment using the signed rank test. The Kruskal-Wallis test was used to test predictors for response to nebulized lidocaine treatment.
Results
Survey Response
Between 2002 and 2007, a total of 165 individuals met the inclusion criteria and were included in the study. This represented only 2.7% of 6,198 people seen for the primary indication of cough in the Division of Pulmonary and Critical Medicine during the same period. Survey response rate was 60% (n 5 99). The 66 patients were excluded for the following reasons: They completed the survey questionnaire but did not send in their Health Insurance Portability and Accountability Act form (n 5 21), refused to participate in the study (n 5 20), did not respond (n 5 16), refused research authorization (n 5 4), returned an incomplete survey (n 5 2), reported that they never used the treatment (n 5 1), denied receiving a prescription for lidocaine (n 5 1), or had died (n 5 1). In the fi nal data set, there were at least 90 responses to each of the questions. There were no more than nine missing responses to each question. The mean (SD) time between clinic visit and completion of the survey was 2.7 (1.6) years. Demographic data are summarized in Table 1 . The median duration of cough was 5 years, and 39 study participants (41%) had cough for Ն 11 years. There were 91 subjects who used the nebulized treatment; seven did not, and there was one missing response ( Table 2 ) .
Safety and Adverse Effects
Among the patients who used nebulized lidocaine ( Table 2 ) , 43% reported at least one adverse effect ( Table 3 ). These are described in Table 3 . The most common adverse effects were unpleasant taste and throat or mouth irritation. Although 9% of patients reported to have choked on water or food, the follow-up phone interview did not identify any studied. Concern exists regarding patient safety, particularly for aspiration pneumonia. We could not fi nd published literature on the long-term safety of selfadministered therapy for symptomatic control of chronic cough. In the present case series, we describe follow-up data on the safety of self-administered nebulized lidocaine for chronic cough.
Materials and Methods
Study Setting and Design
We conducted a retrospective case series of patients seen in a single-center, tertiary pulmonary specialty practice in the Midwest of the United States. The study was conducted in accordance with the Mayo Clinic Institutional Review Board (IRB# 07-002432), which reviewed and approved all patient communication material, including the questionnaire and phone scripts.
Study Subjects
The patient registry in the nurse education log between January 1, 2002, and December 31, 2007 was abstracted to identify all patients who were prescribed a nebulized lidocaine protocol for chronic cough. The recommendation to use nebulized lidocaine was based solely on the evaluating physician's recommendation. Patients were sent a survey if they (1) received a prescription for nebulized lidocaine and completed the nurse education for nebulized lidocaine for chronic cough between 2002 and 2007, and (2) provided a written consent on fi le to use data from their medical record.
Nebulized Lidocaine Dose and Frequency
All patients were instructed to start with 3 mL of 4% lidocaine (120 mg) bid or tid with the option to increase to 5 mL (200 mg) if numbness of the throat lasted , 20 min. All patients received a standard "how to nebulize lidocaine" educational session and had their fi rst dose administered in the clinic under nurse supervision (e-Appendix 1).
Questionnaire Development
The questionnaire was drafted with a primary emphasis on the safety of therapy. A list of reported adverse reactions for nebulized lidocaine was compiled from the literature, including the Micromedex. It was further winnowed down based on the collective experiences of the pulmonary consultants and nurses. Study participants were asked whether nebulized lidocaine use was associated with any adverse events. A write-in line was provided for adverse reactions not otherwise listed.
Questions were included on the impact of therapy and of the ease of use. There were questions regarding adherence to treatment, problems encountered while performing the treatment, and fi nally, the quality of nursing instruction. We asked the patient to estimate cough severity before and after treatment with nebulized lidocaine. Cough severity was rated on a scale from 0 (no cough) to 10 (worst cough). The Department of Survey Research and Biomedical Sta tistics and Informatics at Mayo Clinic in Rochester, Minnesota, reviewed, formatted, and administered the questionnaire.
Survey and Data Collection
The two questionnaire mailings occurred 4 weeks apart. After the second mailing, all nonresponders were contacted directly by it to others. Primary nonadherence was low; seven patients (7%) admitted not even trying the treatment. There were 15 patients (18%) who had trouble getting started with nebulized lidocaine treatment. The main barriers were getting the prescription fi lled by the local pharmacist and obtaining insurance coverage. Once treatment was initiated, 15 reported diffi culty in the actual administration of the nebulized lidocaine treatment. More than one-half had some relief after the treatment, with the majority experiencing the improvement within the fi rst week ( Table 5 ) . Most were able to nebulize at least once a day, and 65% reported immediate relief after use. There were 63 patients who continue to use it for symptomatic control beyond 4 weeks. Some patients discontinued therapy because they were instructed by the evaluating physician to try it for 2 to 4 weeks only. Only 19 (23%) stopped before 4 weeks because the cough was better. Nine patients discontinued treatment because of adverse effects.
Satisfaction With Patient Education and Educational Materials
Most (85%) were satisfi ed with the quality of instructions received for the use of nebulized lidocaine. Most (82%) agreed that "just the right amount of information" was given, and 79% agreed that the written information was clear and easy to understand. Seventy-nine percent agreed that the information on when, how often, and for how long to use nebulized lidocaine medication was clearly explained. Thirty-seven percent instance of aspiration pneumonia that required antibiotic treatment, ED visit, or hospitalization as a direct result of this problem.
Patient Satisfaction With Nebulized Lidocaine, Cough Relief, and Duration of Use
Most of the patients did not like the treatment. Only 34% expressed satisfaction, and only 40% were willing to recommend nebulized lidocaine as a cough treatment ( Table 4 ). There were 42% who expressed dissatisfaction, with 28% who would not recommend Discussion This is, to our knowledge, the largest case series to report on the safety of long-term use of nebulized lidocaine for diffi cult-to-control chronic cough. The main intent of our study was not the therapeutic efficacy of nebulized lidocaine; rather, it was to assess the safety of patient self-administered nebulized lidocaine at home without direct medical supervision. We could not fi nd published literature to provide safety guidance. Since this question is amenable to a retrospective study design, we conducted the survey on patients who were prescribed and had actually used nebulized lidocaine. The inclusion criteria were set after the decision was made to use nebulized lidocaine. were not clear on how to gauge improvement in cough. Forty-seven percent expressed disagreement regarding instructions on when to decrease the dosage and when to stop lidocaine treatment. Only 18% expressed disagreement that enough information on the side effects of lidocaine medication was provided.
Improvement in Cough and Predictors of Response
The mean (SD) symptom score before treatment was 8.4 (1.6); after treatment, it was 5.9 (3.4) ( P , .001). Seventy-two patients (78%) rated their pretreatment cough severity as Ն 8. Of the 92 individuals with paired before and after estimation of cough severity, 49% indicated improvement in their cough after starting nebulized lidocaine, 41% noted no difference, and 10% had worsening of their cough. Among those reporting improvement in cough symptoms and responded to the follow-up survey, 54% had improvement within the fi rst week of treatment, four (9%) in the third or fourth week, and fi ve (11%) after 5 or more weeks ( Table 5 ). None of the predictors (ie, cough severity, length of cough, sex, tobacco use, education level, and the time lag between clinic visit and completion of survey) was signifi cantly associated with treatment response (using any improvement as the dependent variable). abuse of prescription medication containing codeine and hydrocodone in cough syrup (Coricidin HBP [aka "Triple C" or "Skittles"]) in the youth culture has been alarming and was responsible for several celebrity deaths. The growing problem of antitussive abuse, or "Robotripping," in adolescents may in part be due to increased availability without prescription and to convenient access-found in medicine cabinets at home. 29, 30 Antihistaminic agents have also been linked to habituation and abuse. 31 Alternative antitussive medications are needed that are easy to use and readily avail able in local pharmacies and have low abuse potential.
Study Limitations
We report limitations of this study. The survey response rate of 60% makes response bias less likely but does not eliminate this possibility. Recall bias may have occurred because of the time lag between the clinic visit and survey completion, which averaged . 2 years. A retrospective study design is not ideal when evaluating effi cacy of a medication; however, such a study design is effi cient in providing data for a medication that is rarely prescribed (only 165 patients were prescribed nebulized lidocaine out of . 6,000 patients seen for chronic cough in the same period). A fi nal limitation is that this study was restricted to adults; the safety and effi cacy of nebulized lidocaine for children with chronic cough may be different.
Clinical Implications
Where does nebulized lidocaine fi t among treatment options for chronic cough unresponsive to discontinuation of angiotensin-converting enzyme I therapy or to empirical treatment of asthma, gastroesophageal refl ux disorder, or upper airway cough syndrome? Data from this study suggest that nebulized lidocaine is a safe option to consider and that a 2-week trial will identify patients with the most favorable response. In view of the potential for habituation and for abuse of opioids in the management of chronic cough, not to mention other risks of long-term opioid use, our data help inform the discussion among patients and healthcare providers regarding treatment options for the few patients whose chronic cough continues despite use of conventional treatments.
Conclusion
Nebulized lidocaine may be an important treatment option for adults with diffi cult-to-control chronic cough. The data from our study should help healthcare providers inform patients about likelihood of success, treatment burden, and risk of adverse effects. Randomized placebo-controlled trials are needed to In this series of 99 patients with diffi cult-to-control chronic cough, we found that 43% had at least one adverse effect of therapy. Importantly, 9% of individuals in this cohort reported choking on water or food, although no aspiration pneumonia or unscheduled health-care use was associated with these episodes, and 49% reported some degree of relief in their cough after using the nebulized lidocaine. In our analysis, we were unable to identify patient characteristics that predicted a favorable response to nebulized lidocaine.
Our data contribute to the known safety profi le of nebulized lidocaine in that many previous studies were for acute cough, were administered under medical supervision, or were limited to a small number of patients. By following up on survey information with phone calls and direct patient contact, we have more certainty that the frequency of serious adverse events, such as aspiration, is likely low when nebulized lidocaine treatment is used for chronic cough in adults.
Although nebulized lidocaine is in common use for topical anesthesia in bronchoscopy, 16 concern still exists about lidocaine toxicity from mucosal absorption with its long-term use for cough. 9, 15, 17 Pharmacokinetics of topical application and nebulization of lidocaine have been studied for short-term local anesthesia in the pharynx and airway. [18] [19] [20] [21] [22] For lidocaine to be stable in solution, it is formulated as a hydrochloride salt with molecules existing in the quaternary water-soluble state (acid dissociation constant or pKa . 7.4). When exposed to physiologic pH, a tertiary lipid-soluble form is generated that exerts the anesthetic properties of the drug. In infl amed (acidic) mucosa or tissue, the water-soluble form predominates.
In long-term, bid or tid use with normal liver function, nebulized lidocaine should theoretically not accumulate in the serum because the serum half-life of lidocaine is about 90 min. Serum concentration after lidocaine nebulizations for bronchoscopy did not reach levels . 5 m g/mL. 23 However, mucosal absorption may vary depending on the presence of infl ammation. A dosage of 600 mg or 8.2 mg/kg was safely used in patients with asthma who were undergoing research bronchoscopy. 24 Our study is in agreement with clinical studies of nebulized lidocaine as long-term (12-month) therapy for asthma in children and adults. These studies have not reported notable adverse reactions even with total daily doses ranging from 160 mg to 640 mg. 25, 26 Currently available nonnarcotic antitussives are not effi cacious in chronic cough. 5, 27 Although opiates are useful antitussives in suppressing chronic cough, 28 there are concerns about the potential for illicit recreational use and habituation even in legitimate use in the long term. No available statistics track narcotic antitussive abuse separately in the United States. Yet, confi rm the safety and effi cacy of nebulized lidocaine for chronic cough.
